论文部分内容阅读
目的分析经皮行冠状动脉介入术(PCI)联合冠状动脉(冠脉)注射替罗非班治疗急性心肌梗死的疗效。方法 80例急性心肌梗死患者,采用随机数字表法分为观察组和对照组,各40例。观察组实施PCI联合冠脉注射替罗非班治疗,对照组实施单纯PCI治疗,对比两组术前和术后的心肌梗死溶栓分级(TIMI分级)、心血管事件发生情况。结果术前,两组TIMI 3级血流率差异无统计学意义(P>0.05)。术后,观察组的TIMI 3级血流率(90.00%)得到显著提高,且与对照组(70.00%)相比,差异具有统计学意义(P<0.05);观察组与对照组的心血管事件发生率分别为5.00%和20.00%,比较差异具有统计学意义(P<0.05)。结论 PCI联合冠脉注射替罗非班在增加急性心肌梗死的冠脉灌注量、提高安全性等方面具有显著优势,值得临床推广。
Objective To analyze the effect of percutaneous coronary intervention (PCI) combined with coronary (coronary) injection of tirofiban in the treatment of acute myocardial infarction. Methods Eighty patients with acute myocardial infarction were randomly divided into observation group and control group with 40 cases in each group. The observation group was treated with PCI combined with tirofiban in coronary artery. The control group was treated with PCI alone. The preoperative and postoperative myocardial infarction thrombolysis grade (TIMI grade) and cardiovascular events were compared between the two groups. Results Before operation, there was no significant difference in TIMI grade 3 blood flow between the two groups (P> 0.05). After operation, the TIMI grade 3 blood flow rate (90.00%) in the observation group was significantly increased compared with the control group (70.00%), the difference was statistically significant (P <0.05) Incidence rates were 5.00% and 20.00%, respectively, with significant difference (P <0.05). Conclusion PCI combined with tirofiban coronary injection has significant advantages in increasing coronary perfusion and safety in acute myocardial infarction, which is worthy of clinical promotion.